Both BRD4 and NIPBL are indispensable for the proper hematopoietic development (Dey et al., 2019; Mazzola et al., 2020) and both have been related with hematological defects: it has been detected an increased incidence of thrombocytopenia in CdLS patients (Lambert et al., 2011) and in clinical trials where BRD4 inhibitors have been essayed to treat diverse types of cancer, a prominent highly common toxic effect is thrombocytopenia (reviewed in (Sun et al., 2020)). Here, NIPBL is linked to cancer.